Inventor
VRUDHULA VIVEKANANDA M
US23 patents
⚠️ This page may combine multiple inventors who share the name “VRUDHULA VIVEKANANDA M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
16 patentsUS9718804B2Aug 1, 2017
GSK-3 inhibitors
BRISTOL MYERS SQUIBB CO5 citations72
US9708337B2Jul 18, 2017
Aryl amide-based kinase inhibitors
BRISTOL MYERS SQUIBB CO3 citations72
US6888004B2May 3, 2005
Imidazolyl derivatives as corticotropin releasing factor inhibitors
BRISTOL MYERS SQUIBB CO7 citations71
US6939968B2Sep 6, 2005
Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
BRISTOL MYERS SQUIBB CO6 citations67
US7572795B2Aug 11, 2009
Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
BRISTOL MYERS SQUIBB CO3 citations63
US7238699B2Jul 3, 2007
Imidazolyl derivatives as corticotropin releasing factor inhibitors
BRISTOL MYERS SQUIBB CO3 citations62
US6239146B1May 29, 2001
Neurotrophic difluoroamide agents
BRISTOL MYERS SQUIBB CO2 citations62
US6096762AAug 1, 2000
Neurotrophic difluoroamide agents
BRISTOL MYERS SQUIBB CO4 citations62
US8026257B2Sep 27, 2011
Substituted heterocyclic ethers and their use in CNS disorders
BRISTOL MYERS SQUIBB CO4 citations61
US7211669B2May 1, 2007
Imidazolyl derivatives as corticotropin releasing factor inhibitors
BRISTOL MYERS SQUIBB CO2 citations59
US8969564B2Mar 3, 2015
Aryl ether-base kinase inhibitors
BRISTOL MYERS SQUIBB CO0 citations51
US8901305B2Dec 2, 2014
Aryl lactam kinase inhibitors
BRISTOL MYERS SQUIBB CO1 citations51
US8703953B2Apr 22, 2014
Aryl ether-base kinase inhibitors
BRISTOL MYERS SQUIBB CO1 citations51
US8372847B2Feb 12, 2013
Pyrazinone modulator of corticotropin-releasing factor receptor activity
BRISTOL MYERS SQUIBB CO0 citations51
US7932256B2Apr 26, 2011
(S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
BRISTOL MYERS SQUIBB CO0 citations51
US10035777B2Jul 31, 2018
Heterocyclic kinase inhibitors
BRISTOL MYERS SQUIBB CO0 citations41
NEORX CORP
7 patentsUS5112954AMay 12, 1992
Method of enhancing the effect of cytotoxic agents
NEORX CORP147 citations99
US5563250AOct 8, 1996
Cleavable conjugates for the delivery and release of agents in native form
NEORX CORP146 citations97
US5141648AAug 25, 1992
Methods for isolating compounds using cleavable linker bound matrices
NEORX CORP66 citations96
US5521290AMay 28, 1996
Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages and methods for their preparation
NEORX CORP77 citations94
US5066789ANov 19, 1991
Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
NEORX CORP43 citations94
US5017693AMay 21, 1991
Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound
NEORX CORP27 citations92
US5549883AAug 27, 1996
Chemically defined polymeric carriers for release of covalently linked agents
NEORX CORP7 citations72